# US 2020/0170998 A1 · Umbilical cord blood serum and umbilical cord blood plasma preparation in combination with a nonsteroidal anti-inflammatory drug and freeze-drying the composition

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0170998 A1
- Document ID: US20200170998A1
- Status: Published application
- Kind: A1
- Application number: 16/698,896
- Filed: 2019-11-27
- Published: 2020-06-04
- Earliest claimed: 2018-11-29
- Assignees: Cellula LLC
- Applicants: Cellula LLC
- Inventors: Damian Joseph Todd; Dennis Todd
- Web page: https://patentgrep.com/patent/US20200170998A1

## CPC

- A61K 31/407: condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
- A01N 1/125: Freeze protecting agents, e.g. cryoprotectants or osmolarity regulators
- A01N 1/126: Physiologically active agents, e.g. antioxidants or nutrients
- A61K 9/0048: {Eye, e.g. artificial tears}
- A61K 9/19: lyophilised {, i.e. freeze-dried, solutions or dispersions (lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00)}
- A61K 31/573: substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A61K 35/51: Umbilical cord; Umbilical cord blood; Umbilical stem cells
- A61K 38/12: Cyclic peptides {, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C (A61K38/043 - A61K38/046 take precedence)}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A01N: PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF (preservation of food or foodstuff A23); BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES (preparations for medical, dental or toiletry purposes which kill or prevent the growth or proliferation of unwanted organisms A61K); PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS

## Abstract

A process to prepare and freeze-dry umbilical cord blood serum and/or umbilical cord blood plasma with a nonsteroidal anti-inflammatory drug and/or ophthalmic steroids. The freeze dried composition may then be administered using a system for delivering predetermined volumes of the compound to the eye or other parts of the mammalian body.

## Claims

### Claim 1

A composition for the treatment of ocular burns, the composition comprising:
lyophilized umbilical cord blood serum; and
a non-steroidal anti-inflammatory drug (NSAID),
wherein the composition is reconstituted by combination with a sterile solution.

### Claim 2 (depends on 1)

The composition of claim 1, further comprising:
an antibiotic for ophthalmic use.

### Claim 3 (depends on 2)

The composition of claim 2, wherein the antibiotic for ophthalmic use is selected from the group consisting of tobramycin, gentamicin, ciprofloxacin, norfloxacin, and bacitracin.

### Claim 4 (depends on 1)

The composition of claim 1, wherein the NSAID is ketorolac tromethamine.

### Claim 5 (depends on 4)

The composition of claim 4, wherein the ketorolac tromethamine comprises 0.35% to 0.45% weight to volume of the composition.

### Claim 6 (depends on 1)

The composition of claim 1, wherein the NSAID has the following chemical structure:

### Claim 7 (depends on 1)

The composition of claim 1, further comprising:
a ophthalmic steroid.

### Claim 8

A composition for the treatment of ocular burns, the composition comprising:
lyophilized umbilical cord blood serum; and
the non-steroidal anti-inflammatory drug (NSAID) ketorolac tromethamine in an amount between 0.35% to 0.45% by weight,
wherein the composition is reconstituted by combination with a sterile solution.

### Claim 9 (depends on 8)

A method of treating a patient having an ocular burn, the method comprising:
administering a therapeutic amount of the composition of claim 8.
